Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isoliquiritigenin inhibits NLRP3 inflammasome activation with CAPS mutations by suppressing caspase-1 activation and mutated NLRP3 aggregation.

Genes to cells : devoted to molecular & cellular mechanisms - 1 May 2024

Usui-Kawanishi Fumitake, Kani Koudai, Karasawa Tadayoshi, Honda Hiroe, Takayama Nobuyuki, Takahashi Masafumi, Takatsu Kiyoshi, Nagai Yoshinori

Abstract excerpt

The nucleotide-binding oligomerization domain leucine-rich repeat and pyrin domain containing 3 (NLRP3) inflammasome contributes to the development of inflammatory diseases. Cryopyrin-associated periodic syndrome (CAPS) is an autoinflammatory disease caused by NLRP3 gene mutations that results in excessive IL-1β production. We previously identified isoliquiritigenin (ILG), a component of Glycyrrhiza uralensis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 1
Share to Cryopyrin-Associated Periodic Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inflammasomes

Share to Interleukin-1beta

Share to Mutation

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to THP-1 Cells

Source

Identifiers

PMID: 38366709
DOI: 10.1111/gtc.13108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isoliquiritigenin inhibits NLRP3 inflammasome activation with CAPS mutations by suppressing caspase-1 activation and mutated NLRP3 aggregation.PMID 38366709Read ↗

The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunitySemantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndromeSemantic proximity Read ↗

A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants.Semantic proximity Read ↗

The NLRP3 inhibitor MCC950 inhibits IL-1β production in PBMC from 19 patients with Cryopyrin-Associated Periodic Syndrome and in 2 patients with Schnitzler’s SyndromeSemantic proximity Read ↗

Pathogenic NLRP3 mutants forms constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β productionSemantic proximity Read ↗

The NLRP3 Inflammasome as a Pharmacological TargetSemantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

[Pathophysiological mechanisms underlying cryopyrin-associated periodic syndromes: genetic and molecular basis and the inflammasome].Semantic proximity Read ↗

Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3Semantic proximity Read ↗

Glyburide inhibits the Cryopyrin/Nalp3 inflammasome.Semantic proximity Read ↗

Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.